CME Group (NASDAQ: CME) Posts Record Q1 2026 Revenue of $1.88B, Shares Slip 1.17%

NASDAQ: CME · April 22, 2026 · 3 min read

CME Group Inc. (NASDAQ: CME) posted record first-quarter revenue of $1.88 billion, a 14.5% year-over-year increase, yet shares slipped $3.32 (1.17%) to $281.08 as both the top and bottom lines came in fractionally below Wall Street's expectations. Non-GAAP earnings per share of $3.36 fell 0.6% short of the analyst consensus, tempering an otherwise strong operating performance.

Q1 2026 At a Glance

• Revenue: $1.88 billion vs. $1.64 billion in Q1 2025 — up 14.5% year over year
• Non-GAAP EPS: $3.36, missing consensus by 0.6%
• Trailing P/E: 25.1x | Forward P/E: 21.6x
• Net margin: 62.6% | Operating margin: 63.8%
• Gross margin: 100.0% (exchange-model revenue structure)
• Earnings growth (YoY): 35.0% | Revenue growth (YoY): 8.0%
• Share repurchases Q1 2026: 1,809,009 shares for $536 million (0.5% of shares outstanding)
• Cumulative buyback to date: 2,771,612 shares under the December 2024 plan
• 52-week range: $251.90 – $329.16

What Drove the Results

The record revenue reflects the sustained elevation in derivatives trading volumes that has characterized the broader macro environment, where volatility across interest rates, equities, and commodities continues to drive demand for risk management products on CME's exchange. The company's asset-light, high-margin exchange model is clearly visible in its 100.0% gross margin and 63.8% operating margin — structural advantages that allow revenue growth to translate efficiently into earnings, evidenced by 35.0% earnings growth against 8.0% revenue growth this quarter.

Management also demonstrated continued capital discipline. The repurchase of $536 million in stock during Q1 alone — as disclosed in the buyback tranche update — signals confidence in the business even as the share price traded well below its 52-week high of $329.16. The earnings release was confirmed via an SEC EDGAR 8-K filing dated April 22, 2026 (Results of Operations, Item 9.01).

Wall Street View

Analyst sentiment shifted modestly more cautious between March and April. The April 2026 consensus shows 2 Strong Buy, 8 Buy, 7 Hold, and 3 Sell recommendations, compared to 3 Strong Buy, 8 Buy, and 6 Hold in the prior month — reflecting a mild rotation from the most bullish tier into Hold and Sell categories. The incremental downgrade activity likely reflects the modest earnings miss and the stock's proximity to the lower end of its 52-week range, though the majority of covering analysts maintain a constructive stance.

Investor Takeaway

CME Group's Q1 2026 results confirm that its exchange franchise continues to generate record revenues with best-in-class profitability, even as a narrow miss against consensus estimates contributed to today's modest pullback. The company's ongoing share repurchase program and a forward P/E of 21.6x — below the trailing multiple of 25.1x — suggest the market anticipates continued earnings expansion. With the majority of Wall Street analysts still in the Buy camp, the near-term reaction appears measured rather than a reassessment of the underlying business quality.